Clover Health Reports Strong Third Quarter 2024 Financial Results; Highlights Differentiated Market Opportunity to Grow Membership

Delivers 9% Total Revenue growth year-to-date compared to prior year period

Company improves 2024 year-to-date GAAP Net Loss from Continuing Operations by $117.4 million year-over-year and year-to-date Adjusted EBITDA by $87.2 million year-over-year

Increases Full-Year 2024 guidance midpoint to target updated range of Adjusted EBITDA profitability of $55 million - $65 million, strongly positioning the Company to invest in membership growth opportunity for 2025

FRANKLIN, Tenn., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today reported financial results for the third quarter 2024. Management will host a conference call today at 5:00 p.m. ET to discuss its operating results and other business highlights.

"We delivered another strong quarter on all metrics. This demonstrates the strength of our model during a period where other approaches are facing significant headwinds," said Clover Health CEO Andrew Toy. "Underpinned by our ability to use technology to empower any physician on a wide network, our results position us to drive membership growth while maintaining strong underlying financial performance. I am proud that, powered by Clover Assistant, our health plans are anchored on identifying and managing diseases as early as possible to better control the total cost of care. This has also contributed to our market-leading HEDIS performance and achievement of 4.0 Stars for our flagship PPO plan for payment year 2026. We believe this validates our care platform and positions us well to invest in growth in both our core Insurance plans and Counterpart offering."

For the third quarter 2024, GAAP Net loss from continuing operations improved to $8.8 million from $33.6 million in the third quarter of 2023, and Adjusted EBITDA increased to $19.3 million from $2.7 million in the third quarter of 2023. For the year-to-date 2024 period, GAAP Net Loss from continuing operations improved to $24.8 million from a loss of $142.2 million year-to-date in 2023, and year-to-date Adjusted EBITDA increased to $62.3 million in 2024 as compared to a loss of $24.9 million in the 2023 comparable period. Insurance revenue during the third quarter 2024 grew by 7% year-over-year to $322.6 million, and by 9% year-over-year to $1.0 billion on a year-to-date basis, driven by strong member retention and continued intra-year growth. Insurance BER in 2024 improved to 82.8% in the third quarter and 80.6% year-to-date, as compared to 83.3% in the third quarter and 86.2% in the year-to-date period of 2023.

"Our differentiated approach continues to drive our underlying financial momentum," said Clover Health CFO Peter Kuipers. "Strong execution during the third quarter drove meaningful Adjusted EBITDA profitability improvement. As a result, we have increased our full-year 2024 Adjusted EBITDA profitability guidance. We believe that our strong financial profile and momentum, combined with continued strong Stars performance for our flagship PPO plan, sets us up well to invest in and return to membership growth in 2025."

Key Company highlights are as follows:

Dollars in Millions		3Q24				3Q23(1)				Change Between (%)
Insurance revenue		$	322.6			$	301.2			7.1	%
Insurance net medical claims incurred			251.6				236.5			6.4	%
Total revenue			331.0				306.0			8.2	%
Insurance MCR			78.0	%			78.5	%		(50 bps)
Insurance BER(2)			82.8	%			83.3	%		(50 bps)
Salaries and benefits plus General and administrative expenses ("SG&A")(3)		$	90.2			$	101.6			(11.2)	%
Adjusted Salaries and benefits plus General and administrative expenses ("Adjusted SG&A")(4)(5)			61.9				67.5			(8.3)	%
Net loss from continuing operations			(8.8	)			(33.6	)		73.8	%
Adjusted EBITDA(5)			19.3				2.7			614.8	%
Total restricted and unrestricted cash, cash equivalents, and investments		$	531.4			$	672.0			(20.9)	%

Financial Outlook

For full-year 2024, Clover Health is updating its guidance as follows:

	Current 2024 Guidance		Previous 2024 Guidance
Insurance revenue	$1.35 billion - $1.375 billion		$1.35 billion - $1.375 billion
Insurance MCR	76% - 77%		77% - 79%
Insurance BER(5)	81% - 82%		81% - 83%
Adjusted SG&A(5)	$290 million - $295 million		$270 million - $280 million
Adjusted EBITDA(5)	$55 million - $65 million		$50 million - $65 million

¹ The results of operations for the Company's former Non-Insurance segment have been reclassified as discontinued operations for all periods presented due to the Company's decision to not participate in the ACO Reach program for the 2024 performance year. Refer to Note 17 - Discontinued Operations within the Company's most recent Form 10-Q for additional information.

² Insurance Benefits Expense Ratio ("BER") is a Non-GAAP financial measure. A reconciliation of BER to Insurance Net medical claims incurred, net, the most directly comparable GAAP measure, is provided in a table immediately following the consolidated financial statements below. Additional information about the Company's Non-GAAP financial measures can be found under the caption "About Non-GAAP Financial Measures" below and in Appendix A. Beginning in the second quarter 2024, the Company is presenting Insurance BER. Management believes that by adding quality improvement expenses into the Insurance BER calculation, this offers a clearer and more accurate representation of our investment in healthcare quality and member engagement, and more fully captures the cost of maintaining and enhancing the quality of care for our members.

³ Salaries and benefits plus General and administrative expenses ("SG&A") is the sum of Salaries and benefits plus General and administrative expenses presented as the GAAP measure in the condensed consolidated financial statements.

⁴ Adjusted SG&A (Non-GAAP) and Adjusted EBITDA (Non-GAAP) are Non-GAAP financial measures. Reconciliations of Adjusted SG&A (Non-GAAP) to SG&A and Adjusted EBITDA (Non-GAAP) to Net loss from continuing operations, respectively, the most directly comparable GAAP measures, are provided in the tables immediately following the consolidated financial statements below. Additional information about the Company's Non-GAAP financial measures can be found under the caption "About Non-GAAP Financial Measures" below and in Appendix A.

⁵ Reconciliations of projected Adjusted SG&A (Non-GAAP) to projected SG&A, and projected Adjusted EBITDA (Non-GAAP) to Net loss from continuing operations, the most directly comparable GAAP measures, are not provided because Stock-based compensation, which is excluded from Adjusted SG&A (Non-GAAP) and Adjusted EBITDA (Non-GAAP), cannot be reasonably calculated or predicted at this time without unreasonable efforts. A reconciliation of projected Insurance BER (Non-GAAP) to projected Net medical claims incurred, net, the most directly comparable GAAP measure, is not provided because quality improvements, which are included in Insurance BER (Non-GAAP), cannot be reasonably calculated or predicted at this time without unreasonable efforts. Additional information about the Company's Non-GAAP financial measures can be found under the caption "About Non-GAAP Financial Measures" below and in Appendix A.

Lives under Clover Management

	September 30, 2024		September 30, 2023
Insurance members	81,110		81,275

Earnings Conference Call Details

Clover Health's management will host a conference call to discuss its financial results on Wednesday, November 6, at 5:00 PM Eastern Time. To access the call via telephone please dial 800-579-2543 (for U.S. callers) or 785-424-1789 (for callers outside the U.S.) and enter the conference ID: CLOVQ324. A live audio webcast will also be available online at: https://event.on24.com/wcc/r/4738366/21B4058D29B8D4F0F55BC3BAB4EA9B91 and related presentation materials will be available at Clover Health's Investor Relations website at investors.cloverhealth.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link and at Clover Health's Investor Relations website at investors.cloverhealth.com, and will remain available for approximately 12 months.

Upcoming Investor Events & Conferences

• 2024 UBS Global Healthcare Conference at 5:00 p.m. Eastern Time, November 12, 2024
• Canaccord Genuity 2024 Medical Technology, Diagnostics, and Digital Health Forum, November 21, 2024
• 2024 Virtual BTIG Digital Health Forum, November 25, 2024
• 2024 Citi Global Healthcare Conference at 3:15 p.m. Eastern Time, December 3, 2024

Any live and archived webcasts and presentations associated with the conferences listed above may be accessed on Clover Health's Investor Relations website at: investors.cloverhealth.com/news-and-events/investor-events-presentations.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements regarding future events and Clover Health's future results of operations, financial condition, market size and opportunity, business strategy and plans, and the factors affecting our performance and our objectives for future operations. Forward-looking statements are not guarantees of future performance and you are cautioned not to place undue reliance on such statements. In some cases, you can identify forward looking statements because they contain words such as "may," "will," "should," "expects," "plans," "anticipates," "going to," "can," "could," "should," "would," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential," "outlook," "forecast," "guidance," "objective," "plan," "seek," "grow," "if," "continue" or the negative of these words or other similar terms or expressions that concern Clover Health's expectations, strategy, priorities, plans or intentions. Forward-looking statements in this press release include, but are not limited to, the following: statements under "Financial Outlook" and statements regarding expectations relating to potential improvements in Insurance MCR, operating expenses, Adjusted SG&A, Insurance BER, and the number of Clover Health's Insurance members, as well as the statements contained in the quotations of our executive officers, future capital needs and other expectations as to future performance, operations and results (including our updated guidance for full-year 2024). Statements regarding our Adjusted EBITDA profitability are also forward-looking, and are based on our current targets which are preliminary and are derived from our 2024 financial outlook. These statements are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from results expressed or implied by forward-looking statements in this press release. Forward-looking statements involve a number of judgments, risks and uncertainties, including, without limitation, risks related to: our expectations regarding results of operations, financial condition, and cash flows; our expectations regarding the development and management of our Insurance business; our ability to successfully enter new service markets and manage our operations; anticipated trends and challenges in our business and in the markets in which we operate; our ability to effectively manage our beneficiary base and provider network; our ability to maintain and increase adoption and use of Clover Assistant, including the expansion of Clover Assistant for external payors and providers under the brand name Counterpart Assistant; the anticipated benefits associated with the use of Clover Assistant, including our ability to utilize the platform to manage our medical care ratios; our ability to maintain or improve our Star Ratings or otherwise continue to improve the financial performance of our business; our ability to develop new features and functionality that meet market needs and achieve market acceptance; our ability to retain and hire necessary employees and staff our operations appropriately; the timing and amount of certain investments in growth; the outcome of any known and unknown litigation and regulatory proceedings; any current, pending, or future legislation, regulations or policies that could have a negative effect on our revenue and businesses, including rules, regulations, and policies relating to healthcare and Medicare; our ability to maintain, protect, and enhance our intellectual property; general economic conditions and uncertainty; persistent high inflation and interest rates; and geopolitical uncertainty and instability. Additional information concerning these and other risk factors is contained under Item 1A. "Risk Factors" in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 14, 2024, as such risks may be updated in our subsequent filings with the SEC. The forward-looking statements included in this press release are made as of the date hereof. Except as required by law, Clover Health undertakes no obligation to update any of these forward-looking statements after the date of this press release or to conform these statements to actual results or revised expectations.

About Non-GAAP Financial Measures

We use Non-GAAP measures including Insurance BER, Adjusted EBITDA, Adjusted SG&A, and Adjusted SG&A as a percentage of revenue. These Non-GAAP financial measures are provided to enhance the reader's understanding of Clover Health's past financial performance and our prospects for the future. Clover Health's management team uses these Non-GAAP financial measures in assessing Clover Health's performance, as well as in planning and forecasting future periods. These Non-GAAP financial measures are not computed according to GAAP, and the methods we use to compute them may differ from the methods used by other companies. Non-GAAP financial measures are supplemental to and should not be considered a substitute for financial information presented in accordance with generally accepted accounting principles in the United States ("GAAP") and should be read only in conjunction with our consolidated financial statements prepared in accordance with GAAP. Readers are encouraged to review the reconciliations of these Non-GAAP financial measures to the comparable GAAP measures, which are attached to this release, together with other important financial information, including our filings with the SEC, on the Investor Relations page of our website at investors.cloverhealth.com.

For a description of these Non-GAAP financial measures, including the reasons management uses each measure, please see Appendix A: "Explanation of Non-GAAP Financial Measures."

The statements contained in this document are solely those of the authors and do not necessarily reflect the views or policies of CMS. The authors assume responsibility for the accuracy and completeness of the information contained in this document.

About Clover Health:

Clover Health (NASDAQ:CLOV) is a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare. This includes a health equity-based focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. For our members, we provide PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on our flagship wide-network, high-choice PPO plans. For healthcare providers outside Clover Health's Medicare Advantage plan, we aim to extend the benefits of our data-driven technology platform to a wider audience via our subsidiary, Counterpart Health, and to enable enhanced patient outcomes and reduced healthcare costs on a nationwide scale. Clover Health has published data demonstrating the technology's impact on Medication Adherence, as well as the earlier identification and management of Diabetes and Chronic Kidney Disease.

Visit: www.cloverhealth.com

Investor Relations Contact:

Ryan Schmidt

[email protected]

Press Contact:

Andrew Still-Baxter

[email protected]

CLOVER HEALTH INVESTMENTS, CORP. CONDENSED CONSOLIDATED BALANCE SHEETS (Dollars in thousands, except share amounts)
	September 30, 2024 (Unaudited)			December 31, 2023
Assets
Current assets
Cash and cash equivalents	$	287,956		$	116,407
Short-term investments		1,779			12,218
Investment securities, available-for-sale (Amortized cost: 2024: $43,695; 2023: $101,412)		43,302			100,702
Investment securities, held-to-maturity (Fair value: 2024: $15; 2023: $6,778)		15			6,902
Accrued retrospective premiums		20,963			22,076
Other receivables		14,962			16,666
Healthcare receivables		37,314			64,164
Surety bonds and deposits		596			542
Prepaid expenses		12,949			14,418
Other assets, current		2,804			1,404
Assets related to discontinued operations		10,087			72,471
Total current assets		432,727			427,970
Investment securities, available-for-sale (Amortized cost: 2024: $182,840; 2023: $121,868)		184,085			120,208
Investment securities, held-to-maturity (Fair value: 2024: $14,178; 2023: $692)		14,294			793
Property and equipment, net		5,336			5,082
Operating lease right-of-use assets		2,585			3,382
Other intangible assets		2,990			2,990
Other assets, non-current		10,996			10,246
Total assets	$	653,013		$	570,671

CLOVER HEALTH INVESTMENTS, CORP. CONDENSED CONSOLIDATED BALANCE SHEETS (Dollars in thousands, except share amounts)
	September 30, 2024 (Unaudited)				December 31, 2023
Liabilities and Stockholders' Equity
Current liabilities
Unpaid claims	$	166,070			$	135,737
Due to related parties, net		1,340				1,363
Accounts payable and accrued expenses		25,746				37,184
Accrued salaries and benefits		35,340				20,951
Deferred revenue		17				3,099
Operating lease liabilities		1,345				1,665
Other liabilities, current		836				1,017
Liabilities related to discontinued operations		48,941				60,099
Total current liabilities		279,635				261,115
Long-term operating lease liabilities		2,321				2,998
Other liabilities, non-current		28,891				20,164
Total liabilities		310,847				284,277
Commitments and contingencies
Stockholders' equity
Class A Common Stock, $0.0001 par value; 2,500,000,000 shares authorized at September 30, 2024 and December 31, 2023; 411,256,965 and 401,183,882 issued and outstanding at September 30, 2024 and December 31, 2023, respectively		41				40
Class B Common Stock, $0.0001 par value; 500,000,000 shares authorized at September 30, 2024 and December 31, 2023; 89,032,305 and 87,867,732 issued and outstanding at September 30, 2024 and December 31, 2023, respectively		9				9
Additional paid-in capital		2,546,167				2,461,238
Accumulated other comprehensive loss		852				(2,370	)
Accumulated deficit		(2,180,711	)			(2,159,794	)
Less: Treasury stock, at cost; 16,817,010 and 7,912,750 shares held at September 30, 2024 and December 31, 2023, respectively		(24,192	)			(12,729	)
Total stockholders' equity		342,166				286,394
Total liabilities and stockholders' equity	$	653,013			$	570,671

CLOVER HEALTH INVESTMENTS, CORP.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited)
(Dollars in thousands, except per share and share amounts)
	Three Months Ended September 30,								Nine Months Ended September 30,
		2024				2023				2024				2023
Revenues:
Premiums earned, net (Net of ceded premiums of $97 and $106 for the three months ended September 30, 2024 and 2023, respectively; net of ceded premiums of $301 and $341 for the nine months ended September 30, 2024 and 2023, respectively)	$	322,579			$	301,230			$	1,014,201			$	932,699
Other income		8,407				4,798				19,967				15,459
Total revenues		330,986				306,028				1,034,168				948,158
Operating expenses:
Net medical claims incurred		249,774				235,785				763,283				754,836
Salaries and benefits		54,995				60,567				169,717				191,985
General and administrative expenses		35,201				41,030				124,194				140,384
Premium deficiency reserve expense (benefit)		—				392				—				(6,556	)
Depreciation and amortization		339				557				987				1,835
Restructuring (recoveries) costs		(538	)			1,313				288				7,870
Total operating expenses		339,771				339,644				1,058,469				1,090,354
Loss from continuing operations		(8,785	)			(33,616	)			(24,301	)			(142,196	)
Change in fair value of warrants		—				—				17				—
Interest expense		—				—				—				7
Loss on investment		—				—				467				—
Net loss from continuing operations		(8,785	)			(33,616	)			(24,785	)			(142,203	)
Net (loss) income from discontinued operations		(370	)			(7,853	)			3,868				(686	)
Net loss	$	(9,155	)		$	(41,469	)		$	(20,917	)		$	(142,889	)
Per share data:
Basic weighted average number of Class A and Class B common shares and common share equivalents outstanding		490,180,103				480,770,283				488,501,812				480,921,520
Diluted weighted average number of Class A and Class B common shares and common share equivalents outstanding		490,180,103				480,770,283				488,501,812				480,921,520
Continuing operations:
Basic loss per share	$	(0.02	)		$	(0.07	)		$	(0.05	)		$	(0.30	)
Diluted loss per share		(0.02	)			(0.07	)			(0.05	)			(0.30	)
Discontinued operations:
Basic earnings (loss) per share		0.00				(0.02	)			0.01				0.00
Diluted earnings (loss) per share		0.00				(0.02	)			0.01				0.00
Net unrealized gain on available-for-sale investments		3,111				1,643				3,222				4,302
Comprehensive loss	$	(6,044	)		$	(39,826	)		$	(17,695	)		$	(138,587	)

Operating Segments
		Insurance			Corporate/ Other			Eliminations				Consolidated Total
Three Months Ended September 30, 2024		(in thousands)
Premiums earned, net (Net of ceded premiums of $97)		$	322,579		$	—		$	—			$	322,579
Other income			4,314			32,422			(28,329	)			8,407
Intersegment revenues			—			46,944			(46,944	)			—
Net medical claims incurred			251,643			4,442			(6,311	)			249,774
Gross profit (loss)		$	75,250		$	74,924		$	(68,962	)		$	81,212

CLOVER HEALTH INVESTMENTS, CORP. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (Dollars in thousands)
	Nine Months Ended September 30,
		2024				2023
Cash flows from operating activities:
Net loss	$	(20,917	)		$	(142,889	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense		987				1,835
Stock-based compensation		84,686				107,795
Change in fair value of warrants and amortization of warrants		17				—
Accretion, net of amortization		(2,140	)			(3,096	)
Accrued interest earned		(354	)			—
Net realized gains on investment securities		(174	)			(20	)
Loss on investment		467				—
Premium deficiency reserve		—				(6,556	)
Changes in operating assets and liabilities:
Accrued retrospective premiums		1,113				4,741
Other receivables		1,704				8,836
Surety bonds and deposits		(54	)			(17	)
Prepaid expenses		1,469				2,920
Other assets		(2,640	)			5,244
Healthcare receivables		26,850				18,534
Operating lease right-of-use assets		797				405
Unpaid claims		30,310				(24,164	)
Accounts payable and accrued expenses		(11,438	)			2,851
Accrued salaries and benefits		14,389				371
Deferred revenue		(3,082	)			103,295
Other liabilities		8,546				179
Operating lease liabilities		(997	)			(900	)
Net cash provided by operating activities from continuing operations		129,539				79,364
Net cash (used in) provided by operating activities from discontinued operations		(8,861	)			34,060
Net cash provided by operating activities		120,678				113,424
Cash flows from investing activities:
Purchases of short-term investments, available-for-sale, and held-to-maturity securities		(153,347	)			(142,359	)
Proceeds from sales of short-term investments and available-for-sale securities		47,804				60,436
Proceeds from maturities of short-term investments, available-for-sale, and held-to-maturity securities		108,788				139,122
Purchases of property and equipment		(1,241	)			(848	)
Net cash provided by investing activities		2,004				56,351
Cash flows from financing activities:
Issuance of common stock, net of early exercise liability		243				1,149
Repurchases of common stock		(1,772	)			—
Treasury stock acquired		(9,691	)			(5,393	)
Net cash used in financing activities		(11,220	)			(4,244	)
Net increase in cash, cash equivalents, and restricted cash for discontinued and continuing operations		111,462				165,531
Cash, cash equivalents, and restricted cash, beginning of period for discontinued and continuing operations		176,494				186,213
Cash, cash equivalents, and restricted cash, end of period for discontinued and continuing operations	$	287,956			$	351,744
Reconciliation of cash and cash equivalents and restricted cash for discontinued and continuing operations
Cash and cash equivalents	$	287,956			$	299,014
Restricted cash		—				52,730
Total cash, cash equivalents, and restricted cash for discontinued and continuing operations	$	287,956			$	351,744
Supplemental disclosure of non-cash activities
Performance year receivable	$	—			$	(185,404	)
Performance year obligation		—				185,404

CLOVER HEALTH INVESTMENTS, CORP.
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
ADJUSTED EBITDA (NON-GAAP) RECONCILIATION
(in thousands)(1)
	Three Months Ended September 30,
		2024				2023
Net loss from continuing operations (GAAP):	$	(8,785	)		$	(33,616	)
Adjustments
Depreciation and amortization		339				557
Stock-based compensation		27,988				33,070
Premium deficiency reserve expense		—				392
Restructuring (recoveries) costs		(538	)			1,313
Non-recurring legal expenses and settlements		259				1,007
Adjusted EBITDA (Non-GAAP)	$	19,263			$	2,723

(1)	The table above includes Non-GAAP measures. Non-GAAP financial measures are supplemental and should not be considered a substitute for financial information presented in accordance with GAAP. For a detailed explanation of these Non-GAAP measures, see Appendix A.

CLOVER HEALTH INVESTMENTS, CORP. RECONCILIATION OF NON-GAAP FINANCIAL MEASURES ADJUSTED SG&A (NON-GAAP) RECONCILIATION (in thousands)(1)
	Three Months Ended September 30,
		2024				2023
Salaries and benefits	$	54,995			$	60,567
General and administrative expenses		35,201				41,030
Total SG&A (GAAP)		90,196				101,597
Adjustments
Stock-based compensation		(27,988	)			(33,070	)
Non-recurring legal expenses and settlements		(259	)			(1,007	)
Adjusted SG&A (Non-GAAP)	$	61,949			$	67,520
Total revenues (GAAP)	$	330,986			$	306,028
Adjusted SG&A (Non-GAAP) as a percentage of revenue		19	%			22	%

(1)	The table above includes Non-GAAP measures. Non-GAAP financial measures are supplemental and should not be considered a substitute for financial information presented in accordance with GAAP. For a detailed explanation of these Non-GAAP measures, see Appendix A.

CLOVER HEALTH INVESTMENTS, CORP.
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
INSURANCE BENEFITS EXPENSE RATIO (NON-GAAP) RECONCILIATION
(in thousands)(1)
	Three Months Ended September 30,
		2024				2023
Net medical claims incurred, net (GAAP):	$	251,643			$	236,533
Adjustments
Quality improvements		15,445				14,363
Insurance benefits expense, net (Non-GAAP)	$	267,088			$	250,896
Premiums earned, net (GAAP)	$	322,579			$	301,230
Insurance benefits expense ratio, net (Non-GAAP)		82.8	%			83.3	%

(1)	The table above includes Non-GAAP measures. Non-GAAP financial measures are supplemental and should not be considered a substitute for financial information presented in accordance with GAAP. For a detailed explanation of these Non-GAAP measures, see Appendix A.

CLOVER HEALTH INVESTMENTS, CORP.

Appendix A

Explanation of Non-GAAP Financial Measures

Non-GAAP Definitions

Adjusted EBITDA - A Non-GAAP financial measure defined by us as net loss from continuing operations before depreciation and amortization, loss on investment, stock-based compensation, premium deficiency reserve expense (benefit), restructuring (recoveries) costs, and non-recurring legal expenses and settlements. Adjusted EBITDA is a key measure used by our management team and the board of directors to understand and evaluate our operating performance and trends, to prepare and approve our annual budget and to develop short and long-term operating plans. In particular, we believe that the exclusion of the amounts eliminated in calculating Adjusted EBITDA provide useful measures for period-to-period comparisons of our business. Accordingly, we believe that Adjusted EBITDA provides investors and others useful information to understand and evaluate our operating results in the same manner as our management and our board of directors.

Adjusted SG&A - A Non-GAAP financial measure defined by us as total SG&A less stock-based compensation and non-recurring legal expenses and settlements. We believe that Adjusted SG&A provides management, investors, and others a useful view of our operating spend as it excludes non-cash, stock-based compensation and expenses related to investments that management believes do not reflect the Company's core operating expenses. We believe that Adjusted SG&A as a percentage of revenue is useful to management, investors, and others because it allows us to measure our operational leverage as revenue scales.

Insurance Benefits Expense Ratio - A Non-GAAP financial measure defined by us as benefits expense ratio ("BER"). We calculate our Insurance BER by taking the total of Insurance net medical expenses incurred and quality improvements, and dividing that total by premiums earned on a net basis, in a given period. Quality improvements include expenses associated with activities that improve health outcomes, as defined by the U.S. Department of Health and Human Services ("HHS"), as well as those directly tied to enhancing healthcare quality, such as the Company's spend on health information technology, wellness and prevention programs, initiatives to reduce hospital readmissions, and our clinically focused Member Rewards program. We believe our Insurance BER is useful to management, investors, and others because it offers a clearer and more accurate representation of our investment in healthcare quality and member engagement, and gives a comprehensive view of costs related to maintaining and improving the quality of care of our members, which is crucial for sustaining member satisfaction and adherence to treatment regimens.